Triglyceride Variability and Risk of Adverse Cardiovascular Outcomes-Results from the ACCORD Trial

被引：0
|
作者：
Nuyujukian, Daniel S.
Zhou, Jin
Koska, Juraj
Reaven, Peter
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-1240-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1240-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association of Polygenic Risk Score With Blood Pressure and Adverse Cardiovascular Outcomes in Individuals With Type II Diabetes: Insights From the ACCORD Trial
    Parcha, Vibhu
    Pampana, Akhil
    Bress, Adam P.
    Irvin, Marguerite R.
    Arora, Garima
    Arora, Pankaj
    HYPERTENSION, 2022, 79 (05) : E100 - E102
  • [2] Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial
    Packard, Chris J.
    Boren, Jan
    Chapman, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (04)
  • [3] Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes-Results From a Large Territory-Wide Cohort Study
    Kwok, Wang Chun
    Tsui, Chung Ki
    Isaac, Leung Sze Him
    Wong, Chun Ka Emmanuel
    Tam, Terence Chi Chun
    Ho, James Chung Man
    Yap, Desmond Yat Hin
    CLINICAL RESPIRATORY JOURNAL, 2025, 19 (01):
  • [4] Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study
    Junyu Pei
    Xiaopu Wang
    Zeyu Pei
    Xinqun Hu
    Cardiovascular Diabetology, 22
  • [5] Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study
    Pei, Junyu
    Wang, Xiaopu
    Pei, Zeyu
    Hu, Xinqun
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [6] The prognostic value of triglyceride-glucose index to adverse renal outcomes in patients with type 2 diabetes mellitus: results from the cohort study of ACCORD
    Yu, Pan
    Pu, Jiaxi
    Yuan, Qiongjing
    Huang, Ling
    Tao, Lijian
    Peng, Zhangzhe
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [7] Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis
    Hukportie, Daniel Nyarko
    Li, Fu-Rong
    Zhou, Rui
    Zheng, Jia-Zhen
    Wu, Xiao-Xiang
    Zou, Meng-Chen
    Wu, Xian-Bo
    JOURNAL OF DIABETES, 2022, 14 (06) : 365 - 376
  • [8] Adverse Outcomes in Subgroups of Type 2 Diabetes in the ACCORD Clinical Trial
    Rotroff, Daniel M.
    Marvel, Skylar W.
    Jack, John R.
    Havener, Tammy M.
    Doria, Alessandro
    Shah, Hetal S.
    Morieri, Mario-Luca
    Gao, He
    Mychaleckyj, Josyf C.
    Mcleod, Howard L.
    Buse, John B.
    Wagner, Michael J.
    Motsinger-Reif, Alison A.
    DIABETES, 2017, 66 : A121 - A121
  • [9] REPLY: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial Interpret With Caution
    Zahger, Doron
    Schwartz, Gregory G.
    Szarek, Michael
    Fazio, Sergio
    Steg, P. Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (04) : e55 - e55
  • [10] Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
    Margolis, Karen L.
    O'Connor, Patrick J.
    Morgan, Timothy M.
    Buse, John B.
    Cohen, Robert M.
    Cushman, William C.
    Cutler, Jeffrey A.
    Evans, Gregory W.
    Gerstein, Hertzel C.
    Grimm, Richard H., Jr.
    Lipkin, Edward W.
    Narayan, K. M. Venkat
    Riddle, Matthew C., Jr.
    Sood, Ajay
    Goff, David C., Jr.
    DIABETES CARE, 2014, 37 (06) : 1721 - 1728
12345